UNITED GUARDIAN INC (UG) Form 8-K — Nov 9, 2026
United-Guardian (NASDAQ:UG) reported Q3 2026 net sales of $3,494,780, up 54% from $2,264,261 a year ago, with net income surging 247% to $930,912 ($0.20 per share vs. $0.06). Growth was broad-based: pharmaceutical sales rose 29% led by Renacidin following expanded formulary coverage, cosmetic ingredient sales jumped 187% on increased purchases from largest marketing partner Ashland Specialty Ingredients, and medical lubricants grew 20% on Indian customer demand. For the first nine months of 2026, net sales rose 25% to $9,475,269 and net income increased 70% to $2,478,393 ($0.54 per share).
Key figures
- Eps
- 0.2
- Revenue
- 3494780
- Net Income
- 930912
- Revenue Yoy
- 54%
- Nine month eps
- 0.54
- Prior year q3 eps
- 0.06
- Prior year q3 revenue
- 2264261
- Nine month revenue 2025
- 7583613
- Nine month revenue 2026
- 9475269
- Weighted average shares
- 4594319
- Medical lubricants growth
- 20%
- Nine month revenue growth
- 25%
- Nine month net income 2025
- 1456162
- Nine month net income 2026
- 2478393
- Pharmaceutical sales growth
- 29%
- Nine month net income growth
- 70%
- Cosmetic ingredient sales growth
- 187%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.